ESR1 and breast carcinoma: IGFBP2, which was measured in the current study, has been reported to act as a potent mitogenic, by enhancing the proliferative capacity of breast cancer cells, protecting them from chemotherapy-induced apoptosis, and maintaining estrogen-receptor expression [45].